Psoriasis
Not recruitingStudy on the Effectiveness of LY4100511 for Adults with Moderate-to-Severe Plaque Psoriasis
Czechia- Participants:18–64 years · 65+ years
- Substances:Ly4100511
- Sponsor:DICE Therapeutics Inc.
Rare diseases
Investigational molecules
Locations

400 East Jamie Court Suite 300, 94080-6230, United States
Dice Therapeutics Inc. concentrates its clinical research on plaque psoriasis, with studies centered on moderate-to-severe disease in adult participants. The company’s trial portfolio reflects a clear interest in skin inflammation and immune-mediated dermatologic disorders.
Its research activity includes evaluation of therapeutic candidates intended to address the clinical burden of persistent psoriatic skin disease.
DICE Therapeutics Inc. runs clinical trials in conditions such as Psoriasis, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Czechia
The Netherlands
CzechiaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.